Western Blot: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - WB analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, ...read more
Immunocytochemistry/ Immunofluorescence: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. ...read more
In vivo assay: Tat-Beclin 1 L11S Peptide - Scrambled Control [NBP2-49887] - In vivo dose study in mouse kidneys as control for tat-beclin D11 autophagy inducing peptide. Well tolerated by mice at dose of 1mg/kg for 2 ...read more
Tat-Beclin 1 L11S Peptide - Scrambled Control Summary
Description
Tat-L11S [NBP2-49887]: inactive/scrambled control peptides derived from Tat-L11. These peptides are recommended as a negative control. The exact sequence of Tat-Beclin 1 L11S is YGRKKRRQRRRGGNWAWHDFVHIT (Bio-Techne's exclusive patent license: US Patent 8,802,633)
Background
Cell-penetrating autophagy inducing peptides engineered in 2013 were demonstrated to induce autophagy through interaction with the autophagy suppressor GAPR-1/GLIPR2 (Nature, 2013; PMID 23364696). These Tat-Beclin 1 peptides were comprised of AA 267-284 of the autophagy inducer Beclin 1 (18 amino acids), a diglycine linker, and 11 amino acids of the HIV Tat protein transduction domain. Tat-B...eclin 1 peptides were re-engineered to remove 7 AA from the beclin 1 domain. These shorter peptides, Tat-D11 [NBP2-49888] and Tat-L11 [NBP2-49886], demonstrate enhanced autophagy inducing function over the original Tat-Beclin 1 peptides and the inactive/scrambled control peptide Tat-L11S [NBP2-49887]. Tat-D11 and Tat-L11 are potent autophagy inducers which function both in vitro and in vivo to specifically induce autophagy while Tat-L11S is useful as a negative control. Tat-D11 and Tat-L11 peptides are comprised of 11 amino acids of the autophagy-inducing region of beclin 1 fused to the HIV Tat protein. Both Tat-D11 and Tat-L11 peptides function by binding the negative regulator of autophagy GAPR-1/GLIPR2. Upon peptide binding, beclin 1 bound to GARP-1 is released, resulting in beclin 1 mediated autophagosome formation and autophagy induction. Data indicate Tat-D11 is more potent than both Tat-L11 and Tat-Beclin 1 in vivo. In addition, initial data derived from HeLa cells also suggests Tat-D11 is more potent than Tat-L11 in vitro. However, ongoing experiments indicate Tat-L11 may be more potent than Tat-D11 in select cell lines.
Show More
Protein/Peptide Type
Peptide
Applications/Dilutions
Dilutions
Functional
In vitro assay
In vivo assay
Theoretical MW
3.08 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Reviewed Applications
Read 1 Review rated 5 using NBP2-49887 in the following applications:
Publications
Read Publications using NBP2-49887 in the following applications:
Store at -20C in powder form. Store at -80C once reconstituted.
Buffer
This product is supplied lyophilized. Purity is >= to 97% (HPLC)
Reconstitution Instructions
Reconstitute with DMSO or water to desired concetration.
Alternate Names for Tat-Beclin 1 L11S Peptide - Scrambled Control
Autophagy Inducing peptide
Tat-Beclin 1 peptide
Tat-Beclin 1
Tat-Beclin peptide
Tat-Beclin
Tat-L11S
Background
Many standard methods to induce autophagy lack desired specificity. Both starvation and rapamycin, an allosteric inhibitor of MTORC1, are known to regulate biological processes other than autophagy. The non-specific nature of these methods complicates data interpretation and has driven the preference for loss-of-function Atg mutants to analyze autophagy. In 2013, the discovery of engineered Tat-Beclin 1 provided the first method to induce autophagy without regulating other pathways non-specifically. Peptides composed of the autophagy-inducing region of Beclin 1 fused to the HIV-Tat protein were demonstrated to increase autophagosome and autolysosome numbers, as well as protein degradation. Since then, Tat-Beclin 1 peptides have been widely used to successfully induce autophagy both in vitro and in vivo. The peptides below are of a shorter Tat-Beclin 1 peptide with an enhanced potency to induce autophagy. This shorter peptide, Tat-D11, increases autophagosome and autolysosome induction by over fivefold compared to the longer peptide, Tat-Beclin 1. Results have demonstrated the superior potency of Tat-D11 over Tat-Beclin 1.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Publications for Tat-Beclin 1 Peptide (NBP2-49887)(6)
We have publications tested in 1 confirmed species: Human.
We have publications tested in 4 applications: Func, In Vivo, In vitro, WB.
*See also review for tat-beclin D11 autophagy inducing peptide
Used for in vivo dose study in mouse kidneys as control for tat-beclin D11 autophagy inducing peptide. Well tolerated by mice at dose of 1mg/kg for 2 days IP. Soluble in PBS.
Product General Protocols
View specific protocols for Tat-Beclin 1 Peptide (NBP2-49887):
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
![Western Blot: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - WB analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S. The lysates were analyzed for the expression of LC3-1/LC3-II and SQSTM1/p62 using 2ug/ml each of anti-LC3B (NB100-2220) and anti-SQSTM1/p62 (MAB8028) respectively. Anti-Actin (AF4000) was used as a loading control. TatD11 exhibited superior induction of LC3-II and down-regulation of p62 protein when compared to other treatment and control groups.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Autophagy-Inducing-Peptide---Inactive-Form-Western-Blot-NBP2-49887-img0001.jpg "Western Blot: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - WB analysis of lysates from HeLa cells that were left untreated (blank) or were treated with 10-20 uM each of Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S. The lysates were analyzed for the expression of LC3-1/LC3-II and SQSTM1/p62 using 2ug/ml each of anti-LC3B (NB100-2220) and anti-SQSTM1/p62 (MAB8028) respectively. Anti-Actin (AF4000) was used as a loading control. TatD11 exhibited superior induction of LC3-II and down-regulation of p62 protein when compared to other treatment and control groups.")
![Immunocytochemistry/Immunofluorescence: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. Thereafter, the cells were stained using NeuroTrace Red or DAPI and analyzed employing fluorescent microscopy. Note the higher number of autophagosomes/GFP-LC3B+ puncta in the images of Tat-D11 and Tat-L11 treated cells when compared to Tat-Beclin 1 and Tat-L11S treated cells.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Autophagy-Inducing-Peptide---Inactive-Form-Immunocytochemistry-Immunofluorescence-NBP2-49887-img0002.jpg "Immunocytochemistry/Immunofluorescence: Tat-Beclin 1 L11S Autophagy Inducing Peptide - Inactive Form [NBP2-49887] - HeLa GFP-LC3B cells were treated with Tat-D11, Tat-L11, Tat-Beclin 1 or Tat-L11S for 1.5 hours. Thereafter, the cells were stained using NeuroTrace Red or DAPI and analyzed employing fluorescent microscopy. Note the higher number of autophagosomes/GFP-LC3B+ puncta in the images of Tat-D11 and Tat-L11 treated cells when compared to Tat-Beclin 1 and Tat-L11S treated cells.")
![In vivo assay: Tat-Beclin 1 L11S Peptide - Scrambled Control [NBP2-49887] - In vivo dose study in mouse kidneys as control for tat-beclin D11 autophagy inducing peptide. Well tolerated by mice at dose of 1mg/kg for 2 days IP. Soluble in PBS. First two lanes (controls) are treated with 1mg/kg tat-beclin scrambled peptide; remaining lanes are treated with tat-beclin D11 autophagy inducing peptide. Image from verified customer review.](http://images.novusbio.com/fullsize/Tat-Beclin-1-L11S-Peptide---Scrambled-Control-In-vivo-assay-NBP2-49887-img0003.jpg "In vivo assay: Tat-Beclin 1 L11S Peptide - Scrambled Control [NBP2-49887] - In vivo dose study in mouse kidneys as control for tat-beclin D11 autophagy inducing peptide. Well tolerated by mice at dose of 1mg/kg for 2 days IP. Soluble in PBS. First two lanes (controls) are treated with 1mg/kg tat-beclin scrambled peptide; remaining lanes are treated with tat-beclin D11 autophagy inducing peptide. Image from verified customer review.")
![In vivo assay: Tat-Beclin 1 D11 Autophagy Inducing Peptide - Retroinverso form [NBP2-49888] - In vivo dose study in 10wk old C57BL/6J mice. Either 1mg/kg or 10mg/kg IP once daily was administered for 2 days, mice were sacrificed, kidneys prepared for Western blot analysis. Lysosomal inhibitor bafilomycin A1 was used to provide a measurement of autophagic flux. *vehicle is scrambled tat-beclin (NBP2-49887-5mg). Image from verified customer review.](https://images.novusbio.com/images/Tat-Beclin-1-D11-Autophagy-Inducing-Peptide---Retroinverso-form-In-vivo-assay-NBP2-49888-img0004.jpg "In vivo assay: Tat-Beclin 1 D11 Autophagy Inducing Peptide - Retroinverso form [NBP2-49888] - In vivo dose study in 10wk old C57BL/6J mice. Either 1mg/kg or 10mg/kg IP once daily was administered for 2 days, mice were sacrificed, kidneys prepared for Western blot analysis. Lysosomal inhibitor bafilomycin A1 was used to provide a measurement of autophagic flux. *vehicle is scrambled tat-beclin (NBP2-49887-5mg). Image from verified customer review.")
